An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia

@article{Her2017AnIP,
  title={An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia},
  author={Zhisheng Her and Kylie Su Mei Yong and Kathirvel Paramasivam and Wilson Wei Sheng Tan and Xue Ying Chan and Sue Yee Tan and Min Liu and Yong-xing Fan and Yeh Ching Linn and Kam Man Hui and Uttam Surana and Qingfeng Chen},
  journal={Journal of Hematology \& Oncology},
  year={2017},
  volume={10}
}
BackgroundXenotransplantation of patient-derived AML (acute myeloid leukemia) cells in NOD-scid Il2rγnull (NSG) mice is the method of choice for evaluating this human hematologic malignancy. However, existing models constructed using intravenous injection in adult or newborn NSG mice have inferior engraftment efficiency, poor peripheral blood engraftment, or are difficult to construct.MethodsHere, we describe an improved AML xenograft model where primary human AML cells were injected into NSG… 
Acute Myeloid Leukemia Patient-Derived Xenograft Models Generated with the Use of Immunodeficient NSG-SGM3 Mice
Background. Up to the present the survival rates of acute myeloid leukemia (AML) patients have remained low. A successful AML management presupposes generating personalized models of the disease. The
Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias
TLDR
Each leukemia model has a unique localization of tumor cells in several affected organs, which could critically affect the disease course and the efficacy of therapeutic agents, including cellular immunotherapies.
Pilot Study of an Integrative New Tool for Studying Clinical Outcome Discrimination in Acute Leukemia
TLDR
A multifactorial analysis which integrates clinical parameters, ex vivo tumor characterization and behavioral in vivo analysis in zebrafish to understand leukemic primary cells behavior and features associated with aggressiveness and metastatic potential is proposed.
Hematological Humanization of Immune-Deficient Mice.
TLDR
The method to humanize immune-deficient mice with human CD34+ hematopoietic cells is described and the growing field of immune-oncology could benefit from preclinical studies with the humanized mice.
Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review
TLDR
Recent advances in the generation and application of humanized mice models are discussed, new insights into the basic mechanisms, pre‐clinical evaluation of onco‐immunotherapies, current limitations in the application of these models as well as available improvement strategies are reviewed.
Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China
TLDR
This research successfully promoted the approval of SH1573 for clinical trials (CTR20200247) and demonstrated that, as a potential drug against mIDH2 R140Q acute myeloid leukaemia,SH1573 was effective and safe.
Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts
TLDR
It is demonstrated, for the first time, that the content of CTCs and the expression of human CTC markers in PDX blood can be quantified using human-specific qRT-PCR.
Humanized Mice as Unique Tools for Human-Specific Studies
TLDR
This review will focus on the background of humanized mice, diseases, and human-specific therapeutics tested on this platform as well as solutions to improve humanized mouse models for future clinical use.
Isobavachalcone inhibits acute myeloid leukemia: Potential role for ROS‐dependent mitochondrial apoptosis and differentiation
TLDR
This study suggests that the ROS‐medicated signaling pathway is highly involved in IBC‐induced apoptosis and differentiation of AML cells, and exhibited an obvious anti‐AML effect in NOD/SCID mice with the engraftment of HL‐60 cells.
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents
TLDR
Targeting the mechanisms and pathways of CSCs that mediate treatment failure, and potential CSC-targeting agents in various tumors from the clinical perspective might contribute to further drug discovery and therapy.
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
A robust xenotransplantation model for acute myeloid leukemia
TLDR
The NSG xenotransplantation model is a robust model for human AML cell engraftment, which will allow better characterization of AML biology and testing of new therapies, and conclude that animals developed organomegaly and a wasting illness consistent with advanced leukemia.
Human AML cells in NOD/SCID mice: engraftment potential and gene expression
TLDR
The growth of human AML cells in NOD/SCID mice could yield large numbers of humanAML cells for direct experimental use and could also function as a renewable, potentially unlimited source of leukemia cells, via serial transplantation.
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
TLDR
A primary human AML xenotransplantation model using newborn nonobese diabetic/severe combined immunodeficient/interleukin (NOD/SCID/IL)2rγnull mice carrying a complete null mutation of the cytokine γc upon the SCID background is developed, demonstrating that LS cells exclusively recapitulate AML and retain self-renewal capacity in vivo.
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice.
TLDR
It is confirmed that human leukemic stem cells, functionally defined by us as SCID leukemia-initiating cells (SL-ICs), are rare in acute myelogenous leukemia (AML) and suggested a plasticity of the cancer stem cell phenotype that has not been previously described.
Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.
TLDR
The ability of very primitive malignant progenitors from patients with acute myelogenous leukemia to self-renew combined with their potential to differentiate to produce large numbers of more mature progenitor and leukemic blasts suggests that the NOD/SL-IC assay identifies leukedmic 'stem cells' that may maintain the malignant clone in human patients.
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
TLDR
This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
TLDR
Minimal residual disease detected during complete remission was enriched for the CD34(+)CD38(-)ALDH(int) leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse.
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
TLDR
A mouse model of acute promyelocytic leukemia and a small molecule competitive antagonist of CXCR4, AMD3100, are used to examine the interaction of mouse APL cells with the BM microenvironment to provide a proof-of-principle for directing therapy to the critical tethers that promote AML-niche interactions.
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.
TLDR
Evidence that anti-CD38 antibodies have a profound inhibitory effect on engraftment of cord blood and leukemia cells is presented and it is demonstrated that the CD34(+)CD38(+) fraction of certain acute myeloid leukemia samples contains all, or at least most, leukemia-initiating cell capacity.
Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model
TLDR
The data strongly suggest that AML in NOD/SCID does not reflect the leukemic process in the patient, and identifies a series of clinical parameters that determine the NOD-SCID repopulating ability of AML samples.
...
1
2
3
4
5
...